This potent inhibitor of NF-κB, which is highly active in AML stem cells but not normal HSCs, results in apoptosis of both AML and CML blast crisis stem cells, sparing normal HSCs (Guzman et al, 2005). Here, NFKB1 is linked to acute myeloid leukemia.